to accelerate the early clinical development of novel SARS-CoV-2 Mpro antiviral drug
- Funded by Gates Foundation
- Total publications:0 publications
Grant number: INV-037900
Grant search
Key facts
Disease
COVID-19Start & end year
2021Known Financial Commitments (USD)
$6,500,000Funder
Gates FoundationResearch Location
United States of AmericaLead Research Institution
Calibr, a division of The Scripps Research InstituteResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementationResearch Subcategory
Therapeutics logistics and supply chains and distribution strategiesSpecial Interest Tags
N/AStudy Type
UnspecifiedClinical Trial Details
N/ABroad Policy Alignment
PendingAge Group
UnspecifiedVulnerable Population
UnspecifiedOccupations of Interest
Unspecified
Abstract
N/A